Nascent Biotech (Nascent Biotech) EBIT per Share : $-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech EBIT per Share?

Nascent Biotech's EBIT per Share for the three months ended in Dec. 2023 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

During the past 3 years, the average EBIT per Share Growth Rate was 43.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 38.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Nascent Biotech's EBIT per Share or its related term are showing as below:

NBIO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 39.5 Med: 43.5 Max: 55.4
Current: 43.5

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Nascent Biotech was 55.40% per year. The lowest was 39.50% per year. And the median was 43.50% per year.

NBIO's 3-Year EBIT Growth Rate is ranked better than
90.34% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs NBIO: 43.50

Nascent Biotech's EBIT for the three months ended in Dec. 2023 was $-0.36 Mil.

Nascent Biotech EBIT per Share Historical Data

The historical data trend for Nascent Biotech's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech EBIT per Share Chart

Nascent Biotech Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

-0.05

-0.11

-0.01

Nascent Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-0.01	-

Nascent Biotech EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Nascent Biotech's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.078	/	118.569
=	-0.01

Nascent Biotech's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.364	/	167.244
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01

Nascent Biotech (OTCPK:NBIO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Nascent Biotech EBIT per Share Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nascent Biotech (Nascent Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408

Website

https://www.nascentbiotech.com

Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.

Executives

Lowell Thomas Holden	director, officer: CFO	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick	director, officer: President	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price	director, officer: Senior VP Business Development	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas	director	631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy	director, officer: CEO	6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121